(Q50607666)

English

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer

scientific article published on 19 July 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Xiaofei Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Hideki Shimodaira

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Hiroshi Soeda

3

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Keigo Komine

4

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Hidekazu Takahashi

5

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Kota Ouchi

6

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Masahiro Inoue

7

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Masanobu Takahashi

8

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Shin Takahashi

9

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Chikashi Ishioka

10

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

publication date

19 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

21

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

6

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

1091-1101

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Molecular Signals of Epigenetic States

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Colorectal cancer epigenetics: complex simplicity

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Clinical applications of DNA methylation biomarkers in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

MethyLight: a high-throughput assay to measure DNA methylation

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1017-6

21 January 2018

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27435270

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-016-1017-6

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/27435270

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50607666&oldid=2254831350"